Zullo Investment Group’s ImmunityBio IBRX Stock Holding History

Zullo Investment Group’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,000	Closed	-$10.1K	–	404
2022 Q4	$10.1K	Hold	2,000	–	–	0.01%	492
2022 Q3	$10K	Hold	2,000	–	–	0.01%	487
2022 Q2	$7K	Hold	2,000	–	–	﹤0.01%	557
2022 Q1	$11K	Hold	2,000	–	–	0.01%	518
2021 Q4	$12K	Buy	+2,000	New	+$15K	0.01%	500

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SSWM

Sheets Smith Wealth Management Winston-Salem, North Carolina $1B AUM 29.77% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Zullo Investment Group's IBRX Position: Q1 2023 in Review

Zullo Investment Group sold out of ImmunityBio (IBRX) in Q1 2023, closing a stake of 2,000 shares — an estimated $10.1K sold.

Zullo Investment Group first reported a position in IBRX in Q4 2021 and held it in 5 quarters. The position peaked at $12K in Q4 2021. 146 funds tracked by Wall St. Rank hold IBRX as of Q1 2023.

Zullo Investment Group reported no remaining ImmunityBio position as of Q1 2023 after selling out during the quarter.
Zullo Investment Group sold 2,000 ImmunityBio shares in Q1 2023, an estimated $10.1K.
Zullo Investment Group first reported a position in ImmunityBio in Q4 2021 and held it in 5 quarters.
Zullo Investment Group's ImmunityBio position peaked at $12K in Q4 2021.
146 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2023.

Based on Zullo Investment Group's 13F filing for Q1 2023, filed 25 Apr 2023.